{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-121068","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.020270+00:00","generated_at":"2026-05-30T05:22:27.127748+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Stoke Therapeutics Q3 net loss $26.4M; FDA lifts partial clinical hold on zorevunersen; STK-002 Phase 1 delayed","bullets":["Cash, equivalents, and marketable securities $269.2M as of Sep 30, 2024.","Net loss Q3 2024 $26.4M ($0.47/shr) vs $24.5M ($0.55/shr) Q3 2023.","Revenue from Acadia collaboration $4.9M in Q3 2024 vs $3.3M in Q3 2023.","FDA removed partial clinical hold on zorevunersen; plans to provide Phase 3 data and regulatory update by year-end.","Phase 1 study of STK-002 (ADOA) delayed to focus on zorevunersen."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-121068","json":"https://secwatch.observer/filing/0000950170-24-121068.json","markdown":"https://secwatch.observer/filing/0000950170-24-121068.md","text":"https://secwatch.observer/filing/0000950170-24-121068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000095017024121068/0000950170-24-121068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000095017024121068/stok-20241105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:22:27.127748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}